Grid Therapeutics has signed an exclusive license agreement with Duke University to develop the first human derived antibody as a targeted immunotherapy for cancer.
German company Evotec has completed the acquisition of US-based Aptuit.
Vicarius Pharma has secured a CHF21m ($21.8m) investment through a Series A preferred stock financing from private investors.
A new consortium, led by Oxford BioMedica, will take part in a two-year, £2m project focused on gene and cell therapy manufacturing.
Peregrine Pharmaceuticals has cut down its workforce by up to 20%, as part of its efforts to decrease costs and achieve overall profitability.
UK-based regenerative medical company Tissue Regenix Group has completed the acquisition of CellRight Technologies, a US-based specialist in regenerative osteoinductive bone scaffolds.
Takeda Pharmaceutical and Cardurion Pharmaceuticals have created a new cardiovascular development partnership.
Binghamton University researchers have developed a new drug that could possibly limit the progression of Parkinson’s disease and also provide better symptom relief.
Bristol-Myers Squibb has agreed to acquire Boston-based IFM Therapeutics for an upfront payment of $300m to strengthen its oncology pipeline.
VenatoRx Pharmaceuticals, which focuses on discovery and development of novel therapies for highly drug resistant bacterial infections, has been awarded up to $9.4m from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.